Intravenous injection of 68Ga-PMD22

Phase 1Radiopharmaceutical

Intravenous injection of 68Ga-PMD22 is one of 7 small molecule programs targeting Hypoparathyroidism. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismRecruiting

HypoparathyroidismPhase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

2 2

Rocaltrol

Calciferol

Calcium

1 5

EXT608

EExtend Biosciences Inc.

Phase 2

1 6

Intravenous injection of 68Ga-PMD22

PPeking Union Medical College Hospital

Phase 1

1 7

Yorvipath

Ascendis Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

PET/CT1 trial

68Ga-PMD22 PET/CT Examination Targeting CLDN18.2

Unknown status·PPeking Union Medical College Hospital·Phase 1·NCT05937919·10 enrolled

Hypoparathyroidism1 trial

Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

Recruiting·PPeking Union Medical College Hospital·Phase 1·NCT07197450·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Intravenous injection of 68Ga-PMD22. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravenous injection of 68Ga-PMD22 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravenous injection of 68Ga-PMD22. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 1[1]
Company: PPeking Union Medical College Hospital

Intravenous injection of 68Ga-PMD22

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

PET/CT1 trial

Hypoparathyroidism1 trial

References

Drug Info

Quick Facts

Related News